Trial Profile

A Phase 1 trial with CAT-5571 for the potential treatment of cystic fibrosis (CF).

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 17 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CAT 5571 (Primary)
Indications Cystic fibrosis
Focus Therapeutic Use

Most Recent Events

23 Jan 2026 According to a BioCryst Pharmaceuticals media release, Astria Therapeutics has been acquired and merged into BioCryst Pharmaceutical.
09 Nov 2017 According to Catabasis Pharmaceuticals media release, company plans to initiate this trial in second half of 2018 and report top-line results in 2019.
02 Dec 2016 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com